Clinical Importance of Plasma Drug Concentration of Oral Molecular Targeted Drugs for Renal Cell Carcinoma

Authors

  • Shinya Takasaki Department of Pharmaceutical Sciences, Tohoku University Hospital
  • Yoshihide Kawasaki Department of Pharmaceutical Sciences, Tohoku University Hospital, 1-1 Seiryo-machi, Aobaku, Sendai, Miyagi
  • Masafumi Kikuchi Department of Pharmaceutical Sciences, Tohoku University Hospital
  • Akihiro Ito Department of Pharmaceutical Sciences, Tohoku University Hospital, Miyagi
  • Hiroaki Yamaguchi Department of Pharmaceutical Sciences, Tohoku University Hospital, Miyagi
  • Nariyasu Mano Department of Pharmaceutical Sciences, Tohoku University Hospital, Miyagi

DOI:

https://doi.org/10.18433/jpps31816

Abstract

Purpose: Therapeutic drug monitoring (TDM) is widely used in clinical practice to maximize drug efficacy and minimize toxicities. Currently, it is also practiced in the use of oral molecular targeted drugs. The objective of this study was to assess the clinical importance of measuring the systemic concentration of oral molecular targeted drugs used to treat renal cell carcinoma (RCC). Methods: The systemic concentrations of the oral molecular targeted drugs sorafenib, sunitinib, axitinib, pazopanib, and everolimus used for RCC were useful for therapeutic interventions, and clinical outcomes were evaluated retrospectively. Results: The interventional use of systemic drug concentration was confirmed in 26 of 87, and their categories are presented. The systemic concentration of sunitinib was useful in dose reduction and/or discontinuation (n = 10), dose escalation (n = 3), and adherence monitoring (n = 2). Nine of the 10 patients whose dose was reduced showed reduced adverse event. Two patients who were intervened in adherence monitor showed improved adherence. For axitinib, dose reduction and/or discontinuation (n = 1) and dose escalation (n = 6) were confirmed. For pazopanib, dose reduction and/or discontinuation (n = 1) and drug interaction detection (n = 1) were confirmed, both of them were confirmed to have reduced adverse events. For everolimus, dose reduction and/or discontinuation (n = 1) and drug interaction detection (n = 1) were confirmed, a patient with reduced dose recovered from adverse events. Interventions for sorafenib were not identified. Conclusions: This study demonstrated that systemic concentrations of oral molecular targeted drugs for RCC were considered to be clinically useful for dose adjustment, monitoring of treatment adherence, and the detection of drug interactions. Moreover, this information could be successfully used to guide individualized therapy to maximize the antitumor effects of these drugs.

Downloads

Download data is not yet available.

Downloads

Published

2021-03-16

How to Cite

Takasaki, S., Kawasaki, Y. ., Kikuchi, M., Ito, A., Yamaguchi, H., & Mano, N. . (2021). Clinical Importance of Plasma Drug Concentration of Oral Molecular Targeted Drugs for Renal Cell Carcinoma. Journal of Pharmacy & Pharmaceutical Sciences, 24, 127–136. https://doi.org/10.18433/jpps31816

Issue

Section

Clinical Pharmacology and Therapeutics